LXRX ▲ +0.4% - Lexicon Pharmaceuticals, Inc. $LXRX - Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure Lexicon Pharmaceuticals shares rose 0.4% on news that the company announced a post hoc analysis of its SOLOIST-WHF trial showing that sotagliflozin demonstrated consistent results across different baseline blood pressure levels in patients with recent worsening heart failure. The analysis suggests the drug's effectiveness was maintained regardless of patients' starting blood pressure, which could broaden its potential applicability in the heart failure population and support the drug's clinical profile. 31-AUG-2026 08:30 AM ET